Navigation Links
Brandeis studies evaluate visionary approach to improving eyesight
Date:12/2/2009

Waltham, MAJoseph Balboni loves sports. An avid tennis player and golfer, as well as baseball fan, the 46-year-old insurance agent became increasingly frustrated over time as his eyesight dimmed due to keratoconus, a degenerative eye disorder. Unable to return the tennis ball or see the pitch at Red Sox games, he faced the prospect of a corneal transplant to restore his vision and eye comfort.

Then three years ago, Balboni discovered an alternative treatment. He received a gas permeable scleral lens (covering the white of the eye) known as the Boston Ocular Surface Prosthesis (BOS-P) from the Boston Foundation for Sight in Needham, MA. "The scleral lens changed my life," said Balboni. "I am very fortunate because the corneal transplant is an expensive operation with no guarantee of lasting results." Balboni's insurance company paid for the lion's share of the roughly $8,000 for treatment and fitting of the lens, even though insurance coverage of the lens is not routine.

Today, in the December issue of the American Journal of Ophthalmology Brandeis University researchers published a paper appraising the economic benefits of the BOS-P, a highly precise scleral lens used to treat severe cornea or ocular surface disease. A companion paper on the clinical benefits has been published online and will appear in the journal's January issue.

The lens is custom fitted to the eye, vaulting the cornea while submerging the entire corneal surface in a pool of oxygenated artificial tears. Designed to improve vision, reduce eye pain, mitigate light sensitivity, and heal and protect the ocular surface, the lens is used in patients with eye diseases including keratoconus, Stevens-Johnson syndrome, dry eye syndrome, and chronic graft vs. host disease. The BOS-P is also useful in patients whose visual acuity is compromised after many types of eye surgery.

The studies were conducted by a team of researchers at the Heller School of Brandeis University that included William B. Stason, MD, a senior scientist, Donald Shepard, PhD, a professor and researcher, Moaven Razavi, MS, a research associate and PhD candidate, and Deborah S, Jacobs, MD, an ophthalmologist at the Boston Foundation for Sight and Harvard Medical School.

The clinical study assessed visual acuity and visual functioning in 69 patients before and after being fitted with a BOS-P. Using a scale from the National Eye Institute, the researchers reported highly significant improvements in visual functioning scores (from 57.0 to 77.8 on a scale of 0 to 100). Gains in visual acuity were also highly significant.

The economic analysis was then undertaken to assess the cost-effectiveness of the scleral lens for each patient fitted, as well as the economic value of resulting improvements in visual function. The researchers based the economic benefits on improvements in visual functioning and converted these to quality-adjusted-life-years (QALYs), a standardized measurement of health. The average cost-effectiveness of the prosthesis was $24,900 per QALY (a favorable value) and the average benefit-cost ratio was 4 to 1, and even higher, 5.6 to 1, in patients with especially severe eye disease.

The research team commented: "We were pleasantly surprised by the outcomes of our studies, because the scleral lens is an expensive device, but it turned out to be both cost-effective and offer a significant improvement in quality of life."

The studies amplify what Joseph Balboni experienced as soon as he started wearing the BOS-P scleral lens: there is nothing like clear, pain-free vision to change your outlook on life.


'/>"/>

Contact: Laura Gardner
gardner@brandeis.edu
781-736-4204
Brandeis University
Source:Eurekalert

Related medicine news :

1. Brandeis researcher awarded grant to investigate memory and aging
2. Brandeis neuroscientist wins NIH directors Pioneer Award
3. Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory
4. Acuo Technologies Announces a New Offering That Enables Sharing of Imaging Studies Securely and Affordably
5. The straight dope: Studies link parental monitoring with decreased teen marijuana usage
6. Climate studies to benefit from 12 years of satellite aerosol data
7. Indiana U. at APHA: Studies about why men and women use lubricants during sex
8. Federal stimulus funds support studies geared to improving HIV care and prevention
9. New studies explore connection between high stress jobs and GI disorders
10. Practice-changing cancer studies presented at major cancer meeting
11. DATATRAK Announces the Award of New Studies from European Pharmaceutical Clients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , ... December 05, 2016 , ... ... it has been featured in SuperbCrew magazine, a leading online tech news platform ... This interview, now featured on SuperbCrew.com, explores the state of enterprise mobility security ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... today that nominations will be accepted from December 5, 2016 through March ... Awards include the Information Security Executive® of the Year, which recognizes executives ...
(Date:12/5/2016)... ... December 05, 2016 , ... Researchers at Johns Hopkins All ... brains of young athletes. Over the course of three years, researchers will study concussions ... guards. The mouth guards, equipped with special sensors, will track the location and force ...
(Date:12/5/2016)... ... December 05, 2016 , ... Worldwise ®, a leading ... firm kathy ireland® Worldwide for five additional years, announced by Kevin Fick, Worldwise ... licensing agreement three years ago to design and develop the kathy ireland® Loved ...
(Date:12/5/2016)... ... December 05, 2016 , ... “Epilepsy Awareness,” which can be ... sparks a conversation about epilepsy, bearing down on the social stigma and lack ... diagnosed with epilepsy within their lifetime. With such a large percentage of people ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... BOCA RATON, Fla. , Dec. 5, 2016 ... has entered into a multi-product marketing agreement with ... seven (7) injectable products. Under the terms of ... products under its label in the ... approved ANDA,s and one tentatively-approved ANDA. The products ...
(Date:12/5/2016)... and PUNE, India , December 5, ... by Allied Market Research, titled, "Global Cancer Biomarkers Market - ... of cancer biomarkers market is projected to reach $15,737 million ... of 13.3% from 2016 to 2022. Omic technologies segment accounted ... and is expected to maintain its dominance during the forecast ...
(Date:12/5/2016)... 5, 2016  Recently Zymo Research announced an ... known as Horvath,s Clock. Based on this technology, ... service to academic and biopharma scientific researchers to ... other than sperm. The service quantifies ... age versus chronological age following drug treatments and ...
Breaking Medicine Technology: